A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours

被引：10
|
作者：
Jolivet, J.
Dean, E.
Ward, T. H.
Denneny, O.
Jacob, C.
Goodege, P.
Dive, C.
Ranson, M.
机构：
[1] Aegera Therapeut, Montreal, PQ, Canada
[2] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[3] Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3541
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.
    Ranson, M.
    Dive, C.
    Ward, T.
    Cummings, J.
    Connolly, K.
    Evans, S.
    Robson, L.
    Durkin, J.
    Jolivet, J.
    Jodrell, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 135S - 135S
  • [2] A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors.
    Ranson, M
    Dive, C
    Ward, T
    Cummings, J
    Connolly, K
    Evans, S
    Robson, L
    Durkin, J
    Jolivet, J
    Jodrell, D
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9117S
  • [3] Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
    Mahadevan, Daruka
    Chalasani, Pavani
    Rensvold, Diane
    Kurtin, Sandy
    Pretzinger, Chris
    Jolivet, Jacques
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Weiss, Glen J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (03): : 239 - 243
  • [4] Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML
    Schimmer, Aaron D.
    Estey, Elihu H.
    Borthakur, Gautam
    Carter, Bing
    Schiller, Gary J.
    Tallman, Martin S.
    Altman, Jessica K.
    Karp, Judith E.
    Kassis, Jeannine
    Jacob, Christine
    Morris, Stephen
    Jolivet, Jacques
    Andreeff, Michael
    BLOOD, 2008, 112 (11) : 283 - 284
  • [5] Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
    Dean, Emma
    Jodrell, Duncan
    Connolly, Kate
    Danson, Sarah
    Jolivet, Jacques
    Durkin, Jon
    Morris, Stephen
    Jowle, Debra
    Ward, Tim
    Cummings, Jeff
    Dickinson, Gemma
    Aarons, Leon
    LaCasse, Eric
    Robson, Lesley
    Dive, Caroline
    Ranson, Malcolm
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1660 - 1666
  • [6] Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours
    Ranson, Malcolm
    Dean, Emma
    Ward, Tim
    Cummings, Jeff
    Robson, Lesley
    Durkin, Jon
    Jolivet, Jacques
    Jodrell, Duncan
    Dive, Caroline
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3580S - 3580S
  • [7] Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.
    Carter, Bing Z.
    Mak, Duncan H.
    Morris, Stephen
    Borthakur, Gautam
    Estey, Elihu
    Byrd, Anna L.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Andreeff, Michael
    BLOOD, 2008, 112 (11) : 678 - 678
  • [8] Phase I portion of the phase I-II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Lee, A. S.
    Zee, B. C.
    Lai, M.
    Jolivet, J.
    Wong, C. S.
    Chiang, C. L.
    Tong, M.
    Tung, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Lee, Ann Sing
    Zee, Benny C. Y.
    Cheung, Foon Yiu
    Kwong, Philip
    Cheng, Ashley Chi Kin
    Lai, Maria
    Kwok, Chloe
    Chong, Marc
    Jolivet, Jacques
    Chiang, C. L.
    Leung, K. C.
    Siu, Steven
    Lee, Conrad
    Tung, Stewart Yuk
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Lee, Francis A. S.
    Zee, Benny Chung-Ying
    Cheung, Foon Yiu
    Kwong, Philip
    Chiang, Chi Leung
    Leung, Kwong Chuen
    Siu, Steven W. K.
    Lee, Conrad
    Lai, Maria
    Kwok, Chloe
    Chong, Marc
    Jolivet, Jacques
    Tung, Steward
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06): : 609 - 613
12345